EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search

ESAIY

Eisai Co. Ltd.

PINKCommon Stock
$6.21
+2.48%today

No SEC filings for this security

Eisai Co. Ltd. is a foreign or OTC-listed security (PINK) that doesn't file with the SEC, so the grounded research view — financials, filings, insider activity and the call — isn't available. Price and news only.

Key stats

52-week range$5.71 – $8.37
5.7152-week8.37
Market cap
$7.01B
Volume
347K
1Y return
+1.31%
Beta
-0.14

Price · 1Y

$6.21▲ +1.31%
over 1Y
L $5.71EODHDH $8.37

Recent news

market news →
Can Biogen's New Drugs Revive Growth Amid Legacy Sales Slump?Bullish
finance.yahoo.com· 2026-06-26
Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type CBullish
finance.yahoo.com· 2026-06-10
Eisai and CaringKind Launch New Initiative to Address Mealtime and Nutrition Needs for People Living with Alzheimer's Disease and Related DementiasBullish
finance.yahoo.com· 2026-06-01
BioArctic's partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations DayBullish
finance.yahoo.com· 2026-05-25
How Eisai (TSE:4523) Is Reframing Its Story With A Tweaked Fair Value OutlookBullish
finance.yahoo.com· 2026-05-21
ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsightBearish
finance.yahoo.com· 2026-05-20
BioArctic Interim Report for the period January - March 2026Bullish
finance.yahoo.com· 2026-05-20
Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 - March 2027)Bullish
finance.yahoo.com· 2026-05-15

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.